JP2014528914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528914A5 JP2014528914A5 JP2014519307A JP2014519307A JP2014528914A5 JP 2014528914 A5 JP2014528914 A5 JP 2014528914A5 JP 2014519307 A JP2014519307 A JP 2014519307A JP 2014519307 A JP2014519307 A JP 2014519307A JP 2014528914 A5 JP2014528914 A5 JP 2014528914A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tocotrienol
- aciduria
- tocotrienol quinone
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505051P | 2011-07-06 | 2011-07-06 | |
| US61/505,051 | 2011-07-06 | ||
| PCT/US2012/045628 WO2013006737A1 (en) | 2011-07-06 | 2012-07-05 | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231924A Division JP2018030892A (ja) | 2011-07-06 | 2017-12-01 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2019215845A Division JP2020029465A (ja) | 2011-07-06 | 2019-11-28 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528914A JP2014528914A (ja) | 2014-10-30 |
| JP2014528914A5 true JP2014528914A5 (https=) | 2015-09-03 |
| JP6728520B2 JP6728520B2 (ja) | 2020-07-22 |
Family
ID=47437452
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519307A Expired - Fee Related JP6728520B2 (ja) | 2011-07-06 | 2012-07-05 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2017231924A Pending JP2018030892A (ja) | 2011-07-06 | 2017-12-01 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2019215845A Withdrawn JP2020029465A (ja) | 2011-07-06 | 2019-11-28 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231924A Pending JP2018030892A (ja) | 2011-07-06 | 2017-12-01 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
| JP2019215845A Withdrawn JP2020029465A (ja) | 2011-07-06 | 2019-11-28 | メチルマロン酸尿症、イソ吉草酸尿症、および他の有機酸尿症のトコトリエノールキノンによる処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150057363A1 (https=) |
| EP (1) | EP2729004B1 (https=) |
| JP (3) | JP6728520B2 (https=) |
| ES (1) | ES2795798T3 (https=) |
| PT (1) | PT2729004T (https=) |
| WO (1) | WO2013006737A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| WO2017184583A1 (en) * | 2016-04-19 | 2017-10-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| EP3937922A4 (en) * | 2019-03-14 | 2022-11-30 | Hemoshear Therapeutics, Inc. | Methods of treating organic acidemias |
| WO2021007350A1 (en) * | 2019-07-09 | 2021-01-14 | Icagen, Llc | Bcat modulation |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| EP1587960A2 (en) * | 2003-01-30 | 2005-10-26 | Research Development Foundation | Methods and compositions for analysis of mitochondrial-related gene expression |
| EP2471530B1 (en) * | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP1749552A1 (en) * | 2005-07-29 | 2007-02-07 | Neuropharma S.A. | Use of collismycin and derivatives thereof as oxidative stress inhibitors |
| JP2012525397A (ja) * | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| PL2424495T3 (pl) * | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| US20120289476A1 (en) * | 2009-12-11 | 2012-11-15 | Jay Allan Barth | Methods for treating methylmalonic acidemia |
-
2012
- 2012-07-05 US US14/130,903 patent/US20150057363A1/en not_active Abandoned
- 2012-07-05 WO PCT/US2012/045628 patent/WO2013006737A1/en not_active Ceased
- 2012-07-05 ES ES12807735T patent/ES2795798T3/es active Active
- 2012-07-05 JP JP2014519307A patent/JP6728520B2/ja not_active Expired - Fee Related
- 2012-07-05 EP EP12807735.1A patent/EP2729004B1/en active Active
- 2012-07-05 PT PT128077351T patent/PT2729004T/pt unknown
-
2017
- 2017-12-01 JP JP2017231924A patent/JP2018030892A/ja active Pending
-
2018
- 2018-06-26 US US16/019,363 patent/US20180303770A1/en not_active Abandoned
-
2019
- 2019-11-28 JP JP2019215845A patent/JP2020029465A/ja not_active Withdrawn
-
2020
- 2020-09-17 US US17/024,664 patent/US20210145769A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528914A5 (https=) | ||
| Argilés et al. | Are there any benefits of exercise training in cancer cachexia? | |
| US20160166631A1 (en) | Nutraceutical combination for prevention and treatment of type 2 diabetes | |
| JP2019210299A (ja) | ケルセチン配糖体を含有する筋萎縮抑制剤 | |
| US9168308B2 (en) | Compositions and methods for nutritional supplementation | |
| JP2014513065A5 (https=) | ||
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| JP2013503168A5 (https=) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| CA2909160A1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| BR112013031117A8 (pt) | Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| Chiu et al. | Augmentation strategies for clozapine-resistant patients with schizophrenia | |
| JP2008531602A (ja) | 抗癌特性を有する化合物 | |
| AU2018345244A1 (en) | The use of a benzoate containing composition to treat glycine encephalopathy | |
| JP5226980B2 (ja) | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物 | |
| JP2009522260A (ja) | メチシリン耐性黄色ブドウ球菌をオキサシリンに対し感作する組成物および方法 | |
| JP2015500836A5 (https=) | ||
| JP2008509877A (ja) | 通常、ビタミンｃ、マグネシウム、緑茶抽出物を含む心血管系疾患を抑制するための医薬調合物 | |
| Azmin et al. | Micronutrients and Parkinson’s Disease | |
| JP2016534024A (ja) | 熱産生を増大させることができる組成物およびその使用 | |
| CN104540509A (zh) | 用于肝脏再生的药物组合物 | |
| KR20160014136A (ko) | 패혈증 예방 또는 치료용 약학 조성물 | |
| CN103860668B (zh) | 一种治疗溶血性贫血的药物组合物及其应用 |